Project Grant R41AI197272
Award Date 7/22/26
Completion Date 6/30/27
Dollars Obligated $312K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Rutgers The State University of New Jersey $8.74 million on September 10, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish and operate a consortium supporting rigorous evaluation and development of early-stage tuberculosis diagnostics, including drug susceptibility tests. The award funds a fast-paced pipeline combining technology scouting, development mentoring, and clinical testing of TB...
- The National Institute of Allergy and Infectious Diseases awarded $300,000 to Alpacure on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a single-domain antibody-based lateral flow assay for tuberculosis diagnosis. Alpacure will refine a variable heavy chain antibody fragment (VHH) optimization platform using phage-display discovery processes and existing VHH candidates to create a low-cost, low-complexity point-of-care TB diagnostic test. The...
- The National Institute of Allergy and Infectious Diseases awarded Oregon Health & Science University $731,581 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanobody-based diagnostics for tuberculosis. The project addresses the clinical challenge of TB diagnosis in resource-limited settings. Current point-of-care tests lack sufficient sensitivity, and laboratory-based diagnostics require complex infrastructure unavailable in...
- The National Institute of Allergy and Infectious Diseases awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $672,540 on April 17, 2026, for novel pediatric tuberculosis diagnostics using host and microbial biomarkers under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project develops diagnostic tools to address tuberculosis as a leading cause of death in children worldwide, with children accounting for an estimated 14 percent...
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas at Dallas $465,664 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for development and validation of USENSE, an electrochemical point-of-care diagnostic platform for urinary tract infections. USENSE is a portable biosensor designed to quantitate three urinary analytes within 5–10 minutes and apply machine learning diagnostic algorithms to output UTI risk...
- The Centers for Disease Control and Prevention awarded $613,744 to SKM Instruments, Inc. on September 30, 2025, under the Prevention of Disease, Disability, and Death by Infectious Diseases program (CFDA 93.084) to develop an ultra-rapid optical platform for antimicrobial susceptibility testing of pulmonary non-tuberculous mycobacterial infections. Performance occurs in Wyoming, with a period of performance extending through May 31, 2026. The project grant supports the development of...
- The National Institute of Allergy and Infectious Diseases awarded the University of Miami $617,438 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a rapid cell-based diagnostic test for urinary tract infections and antimicrobial resistance screening. The project addresses the clinical need for point-of-care UTI diagnosis and antibiotic selection. Current diagnostic methods—urine analysis and culture—require 1–3 days for results and lack...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of California, San Francisco $358,032 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a systematic evaluation of post-tuberculosis lung disease (PTLD) and its relationship to HIV status. The project, titled "The Sequelae TB Study," will comprehensively characterize PTLD among a prospective cohort of TB survivors in Lusaka, Zambia. The...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $4.760584 million on September 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the Rapid Research for Diagnostics Development in TB Network: Episode 2 (R2D2 TB Network II). UCSF will solicit, review, and prioritize novel tuberculosis diagnostics across different phases of development and use cases for evaluation. The work...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Research Institute $1,033,950 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a tuberculosis vaccine regimen optimized to induce lung-resident T cells. The project, titled "A Prime-Pull TB Vaccine Regimen Optimized to Induce Lung-Resident T Cells," focuses on identifying and testing mRNA-lipid nanoparticle vaccine candidates designed to generate...